Antigen-coated poly α-hydroxy acid based microparticles for heterologous prime-boost adenovirus based vaccinations

Biomaterials

Volumn 34, Issue 10, 2013, Pages 2524-2529

  Lemke, Caitlin D ^a   Geary, Sean M ^a   Joshi, Vijaya B ^a   Salem, Aliasger K ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Adenovirus; Antigen; Cancer; Microparticles; Poly hydroxy acids; Vaccine

Indexed keywords

ADENOVIRUS; ANTITUMOR IMMUNITY; CANCER; CANCER VACCINE; HYDROXY ACIDS; IMMUNOGENICITY; MICRO-PARTICLES; OVALBUMINS; T CELLS; T-CELL RESPONSE; TUMOR PROTECTION; VACCINATION STRATEGY;

ANTIGENS; TUMORS; VACCINES;

CARBOXYLIC ACIDS;

ANTIGEN; HYDROXYACID; OVALBUMIN; POLY ALPHA HYDROXYACID; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VACCINATION; ZETA POTENTIAL;

ADENOVIRIDAE; ANIMALS; ANTIGENS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; HYDROXY ACIDS; MALE; MICE;

ADENOVIRIDAE;

EID: 84872679360     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.030     Document Type: Article

References (43)

1. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012, 104:599-613.
2. Morris E., Hart D., Gao L., Tsallios A., Xue S.A., Stauss H. Generation of tumor-specific T-cell therapies. Blood Rev 2006, 20:61-69.
3. Melief C.J. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992, 58:143-175.
4. + T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999, 170:29-38.
5. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000, 21:163-165.
6. Woodland D.L. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004, 25:98-104.
7. Nolz J.C., Harty J.T. Strategies and implications for prime-boost vaccination to generate memory CD8 T cells. Adv Exp Med Biol 2011, 780:69-83.
8. Pham N.L., Pewe L.L., Fleenor C.J., Langlois R.A., Legge K.L., Badovinac V.P., et al. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. Proc Natl Acad Sci USA 2010, 107:12198-12203.
9. Elzey B.D., Siemens D.R., Ratliff T.L., Lubaroff D.M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer 2001, 94:842-849.
10. Siemens D.R., Elzey B.D., Lubaroff D.M., Bohlken C., Jensen R.J., Swanson A.K., et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol 2001, 166:731-735.
11. Lubaroff D.M., Karan D., Andrews M.P., Acosta A., Abouassaly C., Sharma M., et al. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 2006, 24:6155-6162.
12. Karan D., Krieg A.M., Lubaroff D.M. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 2007, 121:1520-1528.
13. + T cells in the mouse. Prostate Cancer Prostatic Dis 2011, 14:118-121.
14. Lemke C.D., Graham J.B., Geary S.M., Zamba G., Lubaroff D.M., Salem A.K. Chitosan is a surprising negative modulator of cytotoxic CD8(+) T cell responses elicited by adenovirus cancer vaccines. Mol Pharm 2011, 8:1652-1661.
15. Geary S.M., Lemke C.D., Lubaroff D.M., Salem A.K. Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN. Cancer Immunol Immunother 2011, 60:1309-1317.
16. Lubaroff D.M., Konety B.R., Link B., Gerstbrein J., Madsen T., Shannon M., et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009, 15:7375-7380.
17. Hodge J.W., Poole D.J., Aarts W.M., Gomez Yafal A., Gritz L., Schlom J. Modified vaccinia virus Ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 2003, 63:7942-7949.
18. Hodge J.W., Higgins J., Schlom J. Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen. Vaccine 2009, 27:4475-4482.
19. Krupa M., Canamero M., Gomez C.E., Najera J.L., Gil J., Esteban M. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 2011, 29:1504-1513.
20. Zhang H., Wang Y., Liu C., Zhang L., Xia Q., Zhang Y., et al. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother 2012, 61:1857-1867.
21. Odunsi K., Matsuzaki J., Karbach J., Neumann A., Mhawech-Fauceglia P., Miller A., et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 2012, 109:5797-5802.
22. Dai M.S., Vassaux G., Xu M., You R.I., Hsieh Y.F., Ouisse L.H., et al. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer. Vaccine 2012, 30:6903-6911.
23. Osada T., Morse M.A., Hobeika A., Lyerly H.K. Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. Semin Oncol 2012, 39:305-310.
24. Audran R., Peter K., Dannull J., Men Y., Scandella E., Groettrup M., et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003, 21:1250-1255.
25. Haining W.N., Anderson D.G., Little S.R., von Bergwelt-Baildon M.S., Cardoso A.A., Alves P., et al. pH-triggered microparticles for peptide vaccination. J Immunol 2004, 173:2578-2585.
26. Waeckerle-Men Y., Gander B., Groettrup M. Delivery of tumor antigens to dendritic cells using biodegradable microspheres. Methods Mol Med 2005, 109:35-46.
27. D'Souza B., Bhowmik T., Shashidharamurthy R., Oettinger C., Selvaraj P., D'Souza M. Oral microparticulate vaccine for melanoma using M-cell targeting. J Drug Target 2012, 20:166-173.
28. Chablani L., Tawde S.A., Akalkotkar A., D'Souza C., Selvaraj P., D'Souza M.J. Formulation and evaluation of a particulate oral breast cancer vaccine. J Pharm Sci 2012, 101:3661-3671.
29. Intra J., Salem A.K. Characterization of the transgene expression generated by branched and linear polyethylenimine-plasmid DNA nanoparticles in vitro and after intraperitoneal injection in vivo. J Control Release 2008, 130:129-138.
30. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
31. Lutsiak M.E., Robinson D.R., Coester C., Kwon G.S., Samuel J. Analysis of poly(d, l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002, 19:1480-1487.
32. Jilek S., Ulrich M., Merkle H.P., Walter E. Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells. Pharm Res 2004, 21:1240-1247.
33. Zhang X.Q., Dahle C.E., Baman N.K., Rich N., Weiner G.J., Salem A.K. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother 2007, 30:469-478.
34. Goforth R., Salem A.K., Zhu X., Miles S., Zhang X.Q., Lee J.H., et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother 2009, 58:517-530.
35. Clawson C., Huang C.T., Futalan D., Seible D.M., Saenz R., Larsson M., et al. Delivery of a peptide via poly(d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity. Nanomedicine 2010, 6:651-661.
36. Prior S., Gander B., Blarer N., Merkle H.P., Subira M.L., Irache J.M., et al. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci 2002, 15:197-207.
37. Thomas C., Rawat A., Hope-Weeks L., Ahsan F. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol Pharm 2011, 8:405-415.
38. Lubaroff D.M., Karan D. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev 2009, 61:268-274.
39. Basak S.K., Kiertscher S.M., Harui A., Roth M.D. Modifying adenoviral vectors for use as gene-based cancer vaccines. Viral Immunol 2004, 17:182-196.
40. Campos S.K., Barry M.A. Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther 2007, 7:189-204.
41. Raki M., Sarkioja M., Escutenaire S., Kangasniemi L., Haavisto E., Kanerva A., et al. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med 2011, 13:253-261.
42. Walter E., Dreher D., Kok M., Thiele L., Kiama S.G., Gehr P., et al. Hydrophilic poly(dl-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J Control Release 2001, 76:149-168.
43. Sorensen M.R., Holst P.J., Pircher H., Christensen J.P., Thomsen A.R. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Eur J Immunol 2009, 39:2725-2736.